Latisse

Latisse® is an FDA-approved prescription medication proven to grow eyelashes making them longer, fuller, and darker. Clinical studies show that lash fullness can double in as little as 16 weeks.

How To apply

The proper application technique of LATISSE^® solution is demonstrated in this helpful video.

Before & After

Patient's Results

16 week Progression

LATISSE^® (bimatoprost ophthalmic solution) 0.03% Important Information

Approved Use

LATISSE^® is an FDA-approved treatment to grow eyelashes for people with inadequate or not enough lashes.

Important Safety Information

Do not use LATISSE^® if you are allergic to one of its ingredients. If you use/used prescription products for eye pressure problems, use LATISSE^® under doctor care. May cause brown darkening of the colored part of the eye which is likely permanent. LATISSE^® may cause eyelid skin darkening which may be reversible. Only apply at base of upper lashes. DO NOT APPLY to lower lid. Hair may grow outside the treatment area. If you have eye problems/surgery, consult your doctor. Common side effects include itchy and red eyes. If discontinued, lashes gradually return to previous appearance.

These are not all the possible side effects of LATISSE^®. For more information, please talk to your doctor.

Please see LATISSE^® full Product Information.

LAT109783 08/17

Frequently Asked Questions

Kybella (deoxycholic acid) is a liquid solution that can be injected under the skin into specific pockets of fat cells. Once these fat cells are exposed to Kybella, they are permanently destroyed. Kybella is currently FDA-approved for submental fullness (i.e. double-chin). It is also used off-label in other locations including around the armpits to target bra fat bulge on the front and back of the trunk. Patients that are pregnant or breastfeeding should not use Kybella. It should also be avoided in patients with a history of difficulty swallowing or medical conditions involving the neck area (i.e.thyroid disorders).

Patients generally note improvement to submental fullness within a few weeks to 2 months after treatment. The total number of required treatments depends on the distribution and amount of submental fat, as well as your personal treatment goals. Each treatment session is spaced about one month apart, and patients should not receive more than 6 treatments total. The average number of treatments for submental fullness in our office is 2-3 treatments. When targeting fullness around the armpits/bra fat bulge, most patients achieve optimal results in 1-2 treatments.

SCHEDULE CONSULTATION

LATISSE^® (bimatoprost ophthalmic solution) 0.03% Important Information

Indication

LATISSE^® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness, and darkness.

Important Safety Information

Contraindications: LATISSE^® is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients.

Warnings and Precautions: In patients using LUMIGAN^® (bimatoprost ophthalmic solution) or other prostaglandin analogs for the treatment of elevated intraocular pressure (IOP), the concomitant use of LATISSE^® may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN^® for IOP reduction should only use LATISSE^® after consulting with their physician and should be monitored for changes to their intraocular pressure.

Increased iris pigmentation has occurred when bimatoprost solution was administered. Patients should be advised about the potential for increased brown iris pigmentation, which is likely to be permanent.

Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation of bimatoprost in most patients.

There is the potential for hair growth to occur in areas where LATISSE^® solution comes in repeated contact with skin surfaces. Apply LATISSE^® only to the skin of the upper eyelid margin at the base of the eyelashes.

LATISSE^® solution should be used with caution in patients with active intraocular inflammation (eg, uveitis) because the inflammation may be exacerbated. LATISSE^® should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Adverse Reactions: The most frequently reported adverse events were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and periorbital erythema. These reactions occurred in less than 4% of patients.

Postmarketing Experience: The following adverse reactions have been identified during postapproval use of LATISSE^®: dry skin of the eyelid and/or periocular area, eye swelling, eyelid edema, hypersensitivity (local allergic reactions), lacrimation increased, madarosis and trichorrhexis (temporary loss of a few eyelashes to loss of sections of eyelashes, and temporary eyelash breakage, respectively), periorbital and lid changes associated with a deepening of the eyelid sulcus, rash (including macular and erythematous), skin discoloration (periorbital), and vision blurred.

Please see LATISSE^® full Prescribing Information.